IFNL3 and Hepatic fibrosis: This meta-analysis on HCV-1 therapy-naïve or relapser patients found a higher SVR rate in those treated with triple therapy than those with dual therapy, regardless of IL-28B genotype, liver fibrosis, baseline HCV load, and HCV sub-genotype.